A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17) was tested together with preemptive predniso...

Descripción completa

Detalles Bibliográficos
Autores principales: Weissinger, Eva M., Metzger, Jochen, Schleuning, Michael, Schmid, Christoph, Messinger, Diethelm, Beutel, Gernot, Wagner-Drouet, Eva-Maria, Schetelig, Johannes, Baurmann, Herrad, Rank, Andreas, Stolzl, Friedrich, Schäfer-Eckart, Kerstin, Westphal, Karin, Bethge, Wolfgang, von Harsdorf, S., Bunjes, Donald W., Heidenreich, Daniela, Klein, Stefan, Holler, Ernst, Kreipe, Hans H., Jonigk, Danny, Türüchanow, Irina, Raad, Julia, Papkalla, Armin, von der Leyen, Heiko, Hambach, Lothar, Hamwi, Iyas, Ehrlich, Steve, Krauter, Jurgen, Stadler, Michael, Ganser, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179847/
https://www.ncbi.nlm.nih.gov/pubmed/33082512
http://dx.doi.org/10.1038/s41375-020-01059-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179847/
https://www.ncbi.nlm.nih.gov/pubmed/33082512
http://dx.doi.org/10.1038/s41375-020-01059-3

Ejemplares similares